Predict your next investment

Symbotix company logo
COMPUTER HARDWARE & SERVICES | IT Services / IT Solutions & Software Development
symbotix.com

See what CB Insights has to offer

About Symbotix

Symbotix designs and implements advanced business models and interoperable healthcare delivery ecosystems. The company is based in Wake Forest, North Carolina.

Symbotix Headquarter Location

Wake Forest, North Carolina, 27587,

United States

Latest Symbotix News

ASCLEPIOS trials: Arzerra reduces relapse rates in MS

Aug 5, 2020

Disclosures: Hauser reports serving on the advisory board for and holding stock options from Alector, Annexon Biosciences, Bionure, Molecular Stethoscope, Neurona Therapeutics and Symbotix. He also reports travel reimbursement from F. Hoffmann-La Roche AG and Novartis. Please see the study for all other author' relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Among patients with multiple sclerosis, Arzerra was associated with lower annualized relapse rates than Aubagio, according to a pair of phase 3 randomized controlled trials published in The New England Journal of Medicine. Arzerra (ofatumumab, Novartis) is a subcutaneous anti-CD monoclonal antibody that selectively depletes B cells. Aubagio (teriflunomide, Sanofi Genzyme) is an oral inhibitor of pyrimidine synthesis that lowers T-cell and B-cell activation, according to Stephen L. Hauser, MD, director of the University of California, San Francisco Weill Institute for Neurosciences, and colleagues. Reference: Hauser SL, et al. N Engl J Med. 2020;doi:10.1056/NEJMoa1917246 In the ASCLEPIOS I and II clinical trials, 1,882 patients with relapsing multiple sclerosis in 37 countries were randomly assigned to receive 20 mg of ofatumumab every 4 weeks after 20 mg loading doses at days 1, 7 and 14, or 14 mg of teriflunomide daily. Patients received treatment for up to 30 months. Hauser and colleagues found that after a median of 1.6 years, the annualized relapse rates in ASCLEPIOS I were 0.11 in the ofatumumab group and 0.22 in the teriflunomide group (difference = –0.11; 95% CI, –0.16 to –0.06). In ASCLEPIOS II, the rate was 0.1 in the ofatumumab group and 0.25 in the teriflunomide group (difference = –0.15; 95% CI, –0.2 to –0.09). Pooling the trial results together, the percentage of patients with worsening disability at 3 months was 10.9% among ofatumumab recipients and 15% among teriflunomide recipients (HR = 0.66; P = .002). At 6 months, that percentage was 8.1% in the ofatumumab group and 12% in teriflunomide group (HR = 0.68; P = .01). In addition, the percentage of patients with improvement in disability at 6 months was 11% in the ofatumumab group and 8.1% in the teriflunomide group (HR = 1.35; P = .09). The number of gadolinium-enhancing lesions per T-weighted MRI scan, the annualized rate of lesions on T2-weighted MRI, and serum neurofilament light chain levels — but not the change in brain volume — followed the same pattern as the annualized relapse rate, the researchers said. Injection-related reactions occurred in 20.2% of ofatumumab recipients and 15% of teriflunomide recipients, who received placebo for this part of the trial, according to the researchers. Serious infections occurred in 2.5% of ofatumumab recipients and 1.8% of teriflunomide recipients. Hauser said that the results are part of a paradigm shift in MS that has occurred in recent decades. “While there is not yet a cure, a generation ago MS patients typically became cane- or crutch-dependent within 15 or 20 years, but now they often are spared from significant disability,” he said in a press release. “The improvement in MS treatment, especially with drugs that specifically target B cells, is one of the great success stories of medicine." According to Novartis’ website, the FDA is expected complete its review of ofatumumab’s supplemental biologics license application in September. Perspective

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.